Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.
Gemma BrueraSilvia MassaceseFrancesco PepeUmberto MalapelleAntonella Dal MasEugenio CiaccoGiuseppe CalvisiGiancarlo TronconeMaurizio SimmacoEnrico RicevutoPublished in: Therapeutic advances in medical oncology (2019)
The trial was registered at Osservatorio Nazionale sulla Sperimentazione Clinica dei Medicinali (OsSC) Agenzia Italiana del Farmaco (AIFA) Numero EudraCT 2009-016793-32.
Keyphrases
- wild type
- phase ii
- clinical trial
- open label
- phase iii
- squamous cell carcinoma
- small cell lung cancer
- electronic health record
- double blind
- placebo controlled
- locally advanced
- oxidative stress
- big data
- clinical decision support
- study protocol
- radiation therapy
- machine learning
- deep learning
- rectal cancer
- artificial intelligence
- oxide nanoparticles
- quantum dots
- metastatic colorectal cancer